Boston Scientific (BSX) is currently facing a critical technical juncture after its stock price plummeted nearly 33% from its previous peak. The stock is testing long-term support levels that have not been revisited in over a year, drawing significant attention from technical analysts. Market participants have identified the $71.88 level as a pivotal support point that will likely dictate the stock's near-term trajectory. A successful hold above this threshold could trigger a relief rally, whereas a decisive break below it might accelerate the current bearish trend. This development comes as equity traders in the healthcare sector evaluate whether the recent sell-off has reached an exhaustion point. The outcome of this support test is expected to provide clarity on whether BSX can stabilize or if further downside pressure is imminent.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis